Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Common Equity (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Common Equity for 6 consecutive years, with $87.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 22.64% year-over-year to $87.3 million, compared with a TTM value of $87.3 million through Dec 2025, down 22.64%, and an annual FY2025 reading of $87.3 million, down 22.64% over the prior year.
  • Common Equity was $87.3 million for Q4 2025 at Treace Medical Concepts, down from $89.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $157.6 million in Q1 2023 and bottomed at -$684000.0 in Q1 2021.
  • Average Common Equity over 5 years is $99.7 million, with a median of $100.3 million recorded in 2021.
  • Peak annual rise in Common Equity hit 130167.09% in 2021, while the deepest fall reached 137.92% in 2021.
  • Year by year, Common Equity stood at $93.1 million in 2021, then tumbled by 34.97% to $60.5 million in 2022, then skyrocketed by 127.89% to $137.9 million in 2023, then decreased by 18.16% to $112.9 million in 2024, then decreased by 22.64% to $87.3 million in 2025.
  • Business Quant data shows Common Equity for TMCI at $87.3 million in Q4 2025, $89.2 million in Q3 2025, and $97.6 million in Q2 2025.